Gus..."what legal steps are Amarin taking to defend the 93% Cardiovascular Indication against generics which have a constant 43% market share."
Amarin needs to prove intentional infringement on their CVD patents in courts...although everyone knows that infringement has been occurring by...generic companies, physicians, pharmacies, governmental agencies, PBM companies, etc., etc....it has been difficult to prove in courts.
Perhaps forthcoming new patents on Et-EPA, an improvement over Vascepa that gets into the lymphatic system in more concentrated amounts...patents, which Amarin has already applied for, will help solve the problem...Amarin has been inhibited from spending their limited assets on marketing because 50% of the sales of Vascepa are now going to infringing generics...This present situation deprives patients from knowing about the reduction of CVD and the other benefits from taking Vascepa.
News 
Market Data 
Discover 
